Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI model spots AFib recurrence risk after ablation

NCT ID NCT06977516

Knowledge-focused Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study developed an artificial intelligence system that combines patient medical records and doctors' notes to predict whether atrial fibrillation (an irregular heartbeat) will return after a common treatment called ablation. Researchers analyzed data from over 2,500 patients across five hospitals in China. The goal is to give doctors a better tool to identify high-risk patients and improve follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help doctors identify patients at higher risk of AFib returning after ablation, allowing for better follow-up care.
What could go wrong
This is a retrospective study, not a clinical trial testing a treatment. The AI model needs to be validated in real-world settings before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,508 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We plan to extract data from patients diagnosed with atrial fibrillation who underwent their first atrial fibrillation ablation at the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Taizhou Hospital of Zhejiang Province, the Affiliated Hospital of Yunnan University, Jinhua People's Hospital, and Beilun District Hospital. The collected data will include the patient's general information, laboratory tests, preoperative dynamic electrocardiogram text modality, echocardiogram text modality, and surgical procedure. The primary observation endpoint will be atrial fibrillation recurrence (defined as the detection of a persistent atrial arrhythmia lasting more than 30 seconds on ECG or dynamic ECG after ablation), with a follow-up period extending until March 2025.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This study retrospectively analyzed data from patients who underwent AF ablation at five Chinese AF centers: the Fourth Affiliated Hospital of Zhejiang University School of Medicine (ZJU4th, January 2016 to March 2024), Taizhou Hospital of Zhejiang Province (ZJTZH, January 2015 to January 2024), the Affiliated Hospital of Yunnan University (YNH, January 2016 to January 2024), Jinhua People's Hospital (JHPH, January 2020 to January 2024), and Ningbo Beilun Hospital (NBH, January 2020 to January 2024). Exclusion criteria were as follows: 1. Repeat ablation procedures; 2. Valvular AF or AF with NYHA class IV heart failure. 3. Missing Holter ECG or preoperative echocardiography data; 4. Loss to follow-up after ablation;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation recurrence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation recurrence

Contacts and locations

Locations

  • Beilun District People's Hospital

    Ningbo, Zhejiang, 315800, China

  • Jinhua People's Hospital

    Jinhua, Zhejiang, 321000, China

  • Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

    Taizhou, Zhejiang, 317000, China

  • The Affiliated Hospital of Yunnan University

    Kunming, Yunnan, 650000, China

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, 322000, China